Dextran-shelled oxygen-loaded nanodroplets reestablish a normoxia-like pro-angiogenic phenotype and behavior in hypoxic human dermal microvascular endothelium

This is the author's manuscript

Original Citation:
Dextran-shelled oxygen-loaded nanodroplets reestablish a normoxia-like pro-angiogenic phenotype and behavior in hypoxic human dermal microvascular endothelium / Basilico, N; Magnetto, C; D'Alessandro, S; Panariti, A; Rivolta, I; Genova, T; Khadjavi, A; Gulino, Gr; Argenziano, M; Soster, M; Cavalli, R; Giribaldi, G; Guiot, C; Prato, M.. - In: TOXICOLOGY AND APPLIED PHARMACOLOGY. - ISSN 0041-008X. - 288:3(2015), pp. 330-338.

Availability:
This version is available http://hdl.handle.net/2318/1532885 since 2016-11-28T09:58:48Z

Published version:
DOI:10.1016/j.taap.2015.08.005

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Dextran-shelled oxygen-loaded nanodroplets reestablish a normoxia-like pro-angiogenic phenotype and behavior in hypoxic human dermal microvascular endothelium.

Running head: Oxygen nanodroplets in hypoxic dermal endothelium.

Nicoletta Basilico\textsuperscript{a}, Chiara Magnetto\textsuperscript{b}, Sarah D’Alessandro\textsuperscript{c}, Alice Panariti\textsuperscript{d}, Ilaria Rivolta\textsuperscript{d}, Tullio Genova\textsuperscript{e}, Amina Khadjavi\textsuperscript{f}, Giulia Rossana Gulino\textsuperscript{g}, Monica Argenziano\textsuperscript{b}, Marco Soster\textsuperscript{h}, Roberta Cavalli\textsuperscript{h}, Giuliana Giribaldi\textsuperscript{g}, Caterina Guiot\textsuperscript{f}, Mauro Prato\textsuperscript{f,*}

\textsuperscript{a} Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università di Milano, via Pascal 36 – 20133, Milano, Italy
\textsuperscript{b} Istituto Nazionale di Ricerca Metrologica (INRIM), Strada delle Cacce, 91 – 10135, Torino, Italy
\textsuperscript{c} Dipartimento di Scienze Farmacologiche e Biomolecolari, Università di Milano, via Pascal 36 – 20133, Milano, Italy
\textsuperscript{d} Dipartimento di Scienze della Salute, Università di Milano Bicocca, Via Cadore 48 – 20900, Monza, Italy
\textsuperscript{e} Dipartimento di Scienze della Vita e Biologia dei Sistemi, Via Accademia Albertina 13, 10123, Torino, Italy
\textsuperscript{f} Dipartimento di Neuroscienze, Università di Torino, Corso Raffaello 30 – 10125, Torino, Italy
\textsuperscript{g} Dipartimento di Oncologia, Università di Torino, Via Santena 5 bis – 10126, Torino, Italy
\textsuperscript{h} Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, Via Giuria, 9 – 10125, Torino, Italy

* corresponding author: Dr. Mauro Prato, Dipartimento di Neuroscienze, Università di Torino, Corso Raffaello 30, 10125 Torino, Italy; Phone: +39-011-670-8198; Fax:+39-011-670-8174; e-mail: mauro.prato@unito.it
E-mail addresses:

Nicoletta Basilico: nicoletta.basilico@unimi.it
Chiara Magnetto: c.magnetto@inrim.it
Sarah D’Alessandro: sarah.dalessandro@unimi.it
Alice Panariti: alice.panariti@mail.mcgill.ca
Ilaria Rivolta: ilaria.rivolta@unimib.it
Tullio Genova: tullio.genova@unito.it
Amina Khadjavi: amina.khadjavi@unito.it
Giulia Rossana Gulino: giuliarossana.gulino@unito.it
Monica Argenziano: monica.argenziano@unito.it
Marco Soster: marco.soster@unito.it
Roberta Cavalli: roberta.cavalli@unito.it
Giuliana Giribaldi: giuliana.giribaldi@unito.it
Caterina Guiot: caterina.guiot@unito.it
Mauro Prato: mauro.prato@unito.it

Funding sources: The work was funded by Compagnia di San Paolo (Ateneo-San Paolo 2011 ORTO11CE8R grant to CG and MP) and Università degli Studi di Torino (ex-60% 2013 intramural funds to GG and MP). MP holds a professorship granted by Università degli Studi di Torino and Azienda Sanitaria Locale-19 (ASL-19). AK and MP are funded by a partnership grant from the European Community and the Italian Ministry of Instruction, University, and Research (CHIC grant no. 600841). NB and SDA research is supported by the Italian Ministry of Instruction, University, and Research (PRIN 2013 grant).
Conflict of interest disclosure: Roberta Cavalli, Caterina Guiot and Mauro Prato have a patent no. WO2015/028901 A1 (A nanostructure for the vehiculation of gas and/or active ingredients and/or contrast agents and use thereof) issued. The other authors have nothing to disclose.
Abstract

In chronic wounds, hypoxia seriously undermines tissue repair processes by altering the balances between pro-angiogenic proteolytic enzymes (matrix metalloproteinases, MMPs) and their inhibitors (tissue inhibitors of metalloproteinases, TIMPs) released from surrounding cells. Recently, we have shown that in human monocytes hypoxia reduces MMP-9 and increases TIMP-1 without affecting TIMP-2 secretion, whereas in human keratinocytes it reduces MMP-2, MMP-9, and TIMP-2, without affecting TIMP-1 release. Provided that the phenotype of the cellular environment is better understood, chronic wounds might be targeted by new oxygenating compounds such as chitosan- or dextran-shelled and 2H,3H-decafluoropentane-cored oxygen-loaded nanodroplets (OLNs). Here, we investigated the effects of hypoxia and dextran-shelled OLNs on the pro-angiogenic phenotype and behavior of human dermal microvascular endothelium (HMEC-1 cell line), another cell population playing key roles during wound healing. Normoxic HMEC-1 constitutively released MMP-2, TIMP-1 and TIMP-2 proteins, but not MMP-9. Hypoxia enhanced MMP-2 and reduced TIMP-1 secretion, without affecting TIMP-2 levels, and compromised cell ability to migrate and invade the extracellular matrix. When taken up by HMEC-1, nontoxic OLNs abrogated the effects of hypoxia, restoring normoxic MMP/TIMP levels and promoting cell migration, matrix invasion, and formation of microvessels. These effects were specifically dependent on time-sustained oxygen diffusion from OLN core, since they were not achieved by oxygen-free nanodroplets or oxygen-saturated solution. Collectively, these data provide new information on the effects of hypoxia on dermal endothelium and support the hypothesis that OLNs might be used as effective adjuvant tools to promote chronic wound healing processes.

Keywords: oxygen; nanodroplet; matrix metalloproteinase (MMP); tissue inhibitor of metalloproteinase (TIMP); human microvascular endothelial cell (HMEC); skin.
Introduction

After injury, skin integrity must be restored promptly to reestablish the homeostatic mechanisms, minimize fluid loss, and prevent infection [Greaves et al., 2013]. This is achieved through wound healing, a complex biological process where multiple pathways are simultaneously activated to induce tissue repair and regeneration. Traditionally, acute wound healing is defined as a complex multi-step and multi-cellular process, distinguished in four phases involving different cell types: i) hemostasis, involving platelets; ii) inflammation, involving neutrophils, monocytes, and macrophages; iii) proliferation, involving keratinocytes, endothelial cells, and fibroblasts; and iv) matrix remodeling, involving keratinocytes, myofibroblasts, and endothelial cells. [Diegelmann et al., 2004]. In particular, during the third and fourth phases, the endothelium plays a pivotal role, since wound microvasculature is rebuilt through angiogenesis to restore the supply of oxygen, blood constituents and nutrients to the regenerating tissue, helping to promote fibroplasia and prevent sustained tissue hypoxia [Eming et al., 2014]. Notably, oxygen represents a key regulator of normal wound healing since it is required for collagen deposition, epithelialization, fibroplasia, angiogenesis, and resistance to infection [Castilla et al., 2012; Sen, 2009]. Once complete, these processes must be shut down in a precise order to prevent exaggerated or delayed responses.

In some cases, the combination of systemic (e.g. diabetes, vascular insufficiency, or ageing) or localized (e.g. bacterial infections and dysregulated proteolysis) factors produce persistent pathological inflammation resulting in chronic wound formation [Diegelmann et al., 2004]. A chronic wound is defined as a break in skin epithelial continuity lasting more than 42 days. Its prevalence varies with age, ranging approximately from 1% in the adult population to 3–5% in >65 year-old subjects [Greaves et al., 2013]. Approximately 7 million patients are...
affected by chronic wounds in the United States, and an estimated $25 billion dollars is spent
annually on the treatment of these wounds [Castilla et al., 2012].

A typical feature of chronic wounds is unbalanced proteolytic activity, which overwhelms
tissue protective mechanisms [Diegelmann et al., 2004; Pepper, 2001]. Within chronic
wounds, activated cells such as endothelial, epithelial, and immune cells display increased
production of proteases, including cathepsin G, urokinase and neutrophil elastase [Greaves et
al., 2013]. Furthermore, pro-inflammatory cytokines strongly induce the production of matrix
metalloproteinases (MMPs) and down-regulate the levels of tissue inhibitors of
metalloproteinases (TIMPs), thereby creating an environment with unbalanced MMP/TIMP
ratios [Diegelmann et al., 2004; Pepper, 2001]. Consequently, wound repair mediators
become targets of proteases, and the resultant matrix degradation contributes to the delay in
re-epithelialization, fibroplasia and angiogenesis [Pepper, 2001; Wells et al., 2015].

However, the effects of hypoxia on the secretion of MMPs and TIMPs by the cellular
environment of the wound are dramatically different depending on the considered cell type.
Therefore, it is extremely important to assess carefully the effects of hypoxia on each single
cell population participating to the wound healing process, from monocytes and keratinocytes
to endothelial cells and fibroblasts. In a couple of recent works published by our group
hypoxia was shown to reduce MMP-9 and increase TIMP-1 without affecting TIMP-2
secretion by human monocytes [Gulino et al., 2015], whereas in human keratinocytes
hypoxia was shown to reduce MMP-2, MMP-9, and TIMP-2 secretion without changing
TIMP-1 levels [Khadjavi et al., 2015]. On the other hand, the effects of hypoxia on the
secretion of gelatinases and their inhibitors by dermal microvascular endothelium still needed
further investigation.

Provided the phenotype of the cellular environment at the milieu of the wound is better
understood, new therapeutic approaches addressing hypoxia might help to face chronic
wounds. For this reason, the major role played by oxygen in essential wound healing processes has attracted considerable clinical interest and yielded compelling data [Sen, 2009]. Additionally, scientific studies targeting the signaling pathways underlying oxygen response within the milieu of the wound tissue are helping to better understand the biochemical pathways involved in hypoxia sensing/response systems. This appears extremely crucial in order to exploit new oxygenating treatments targeting hypoxia-response mechanisms within the healing tissue, thus making them useful in the clinical management of chronic wounds.

So far, hyperbaric oxygen therapy remains a well-established, adjunctive treatment for diabetic lower extremity wounds, when refractory to standard care practices [Sen, 2009]. However, hyperbaric oxygen therapy is expensive and uncomfortable. Moreover, further rigorous randomized trials are needed to properly validate the outcomes of hyperbaric oxygen therapy on chronic wounds associated with other pathologies (arterial ulcers, pressure ulcers, and venous ulcers). Topical oxygen therapy, based on an O₂ gas emulsion applied to the superficial wound tissue, represents another promising approach to enhance the oxygenation of wounded tissues [Sen, 2009]. Major advantages of topical oxygen therapy appear to be its independence of the wound microcirculation, its lower cost with respect to systemic oxygen therapy, lower risks of oxygen toxicity, and its relative simplicity of handling and application. In this context, intensive research is being pursued to develop new carriers able to release therapeutically significant amounts of oxygen to tissues in an effective and time-sustained manner, such as hemoglobin- or perfluorocarbon-based systems [Cabrales et al., 2013; Schroeter et al., 2010]. Among the options currently under investigation, perfluoropentane (PFP)-based oxygen-loaded nanobubbles have been proposed as efficient and biocompatible ultrasound (US)-responsive tools for oxygen delivery [Cavalli et al., 2009a; Cavalli et al., 2009b]. Furthermore, oxygen-loaded nanodroplets (OLNs), constituted by 2H,3H-decafluoropentane (DFP) as core fluorocarbon and dextran or chitosan as shell
polysaccharides, have been recently developed, characterized, and patented by our group as innovative and nonconventional platforms of oxygen nanocarriers, available in formulations suitable for topical treatment of dermal tissues [Magnetto et al., 2014; Prato et al., 2015]. Intriguingly, while keeping all the advantages of nanobubbles, OLNs display higher stability and effectiveness in oxygen storage and release, lower manufacturing costs and ease of scale-up. Encouragingly, chitosan-shelled OLNs proved effective in counteracting the dysregulating effects of hypoxia on secretion of gelatinases and TIMPs by human keratinocytes [Khadjavi et al., 2015], whereas dextran-shelled OLNs abrogated hypoxia-dependent alteration of MMP-9/TIMP-1 balances in human monocytes [Gulino et al., 2015].

To go beyond the current knowledge on MMP/TIMP dysregulation in the different cell populations within the milieu of chronic wounds and expand the available evidence on OLN effectiveness, in the present work we explored the effects of hypoxia and OLNs on the pro-angiogenic phenotype and behavior of human dermal endothelium. To this purpose, a human dermal microvascular endothelial cell line (HMEC-1) was cultured in vitro both in normoxic and hypoxic conditions, in the presence or absence of dextran-shelled OLNs. Then, cells were challenged for their viability, proteolytic phenotype (secretion of gelatinases and their inhibitors), and wound healing abilities [migration, invasion of the extracellular matrix (ECM), and formation of microvessel-like structures].
Methods

Materials

All materials were from Sigma-Aldrich, St Louis, MO, aside from those listed below. Sterile plastics were from Costar, Cambridge, UK; MCDB 131 medium was from Invitrogen, Carlsbad, CA; foetal calf serum was from HyClone, South Logan, UT; epidermal growth factor was from PeproTech, Rocky Hill, NJ; Cultrex was from Trevigen, Gaithersburg, MD; LDH Cytotoxicity Assay kit was from Biovision, Milpitas, CA; enzyme-linked immunosorbent assay (ELISA) kit for human MMP-2 was from Abnova, Taipei City, Taiwan; ELISA kits for human MMP-9, TIMP-1 and TIMP-2 were from RayBiotech, Norcross, GA; electrophoresis reagents and computerized densitometer Geldoc were from Bio-rad Laboratories, Hercules, CA; Synergy Synergy 4 microplate reader was from Bio-Tek Instruments, Winooski, VT; recombinant proMMP-9 and MMP-9 were produced and kindly gifted by Prof. Ghislain Opdenakker and Prof. Philippe Van den Steen; ethanol (96%) was obtained from Carlo Erba (Milan, Italy); culture implants for wound healing assay were from Ibidi GmbH (Planegg/Martinsried, Germany); Epikuron 200® (soya phosphatidylcholine 95%) was from Degussa (Hamburg, Germany); palmitic acid, DFP, dextran sodium salt (100 kDa), and polyvinylpyrrolidone were from Fluka (Buchs, Switzerland); ultrapure water was obtained using a 1-800 Millipore system (Molsheim, France); Ultra-Turrax SG215 homogenizer was from IKA (Staufen, Germany); Delsa Nano C analyzer was from Beckman Coulter (Brea, CA); Philips CM10 instrument was from Philips (Eindhoven, The Netherlands); XDS-3FL microscope was from Optika (Ponteranica, Italy); ECLIPSE Ti inverted microscope was from Nikon (Amsterdam, The Netherlands).

Dextran-shelled nanodroplet preparation and characterization
OLNs, oxygen-free nanodroplets (OFNs), and oxygen-saturated solution (OSS) were prepared as previously described [Prato et al., 2015]. Briefly, 1.5 ml DFP, 0.5 ml polyvinylpyrrolidone and 1.8 ml Epikuron® 200 (solved in 1% w/v ethanol and 0.3 % w/v palmitic acid solution) were homogenized in 30 ml phosphate-buffered saline (PBS) solution (pH 7.4) for 2 min at 24000 rpm by using Ultra-Turrax SG215 homogenizer. For OLNs, the solution was saturated with O₂ for 2 min. Finally, 1.5 ml dextran or fluorescein isothiocyanate (FITC)-labeled dextran solution was added drop-wise whilst the mixture was homogenized at 13000 rpm for 2 min. For OFN and OSS PBS formulations, OLN preparation protocol was applied omitting O₂ or dextran/DFP addition, respectively. Immediately after manufacturing, nanodroplets were sterilized through ultraviolet (UV)-C ray exposure for 20 min and characterized for: morphology and shell thickness, by optical and transmitting electron microscopy; size, particle size distribution, polydispersity index and zeta potential, by dynamic light scattering; refractive index by polarizing microscopy; viscosity and shell shear modulus by rheometry; and oxygen content (before and after UV-C sterilization) through a chemical assay as previously described [Magnetto et al., 2014;Prato et al., 2015].

Cell cultures
A long-term cell line of dermal microvascular endothelial cells (HMEC-1) immortalized by SV 40 large T antigen [Ades et al., 1992] was kindly provided by the Center for Disease Control, Atlanta, GA. Cells were maintained in MCDB 131 medium supplemented with 10% foetal calf serum, 10 ng/ml of epidermal growth factor, 1 µg/ml of hydrocortisone, 2mM glutamine, 100 units/ml of penicillin, 100 µg/ml of streptomycin and 20 mM Hepes buffer, pH7.4. Before the experiments, HMEC-1 were seeded at 10⁵ cells/0.5 ml per well in 24-well flat bottom tissue culture clusters and incubated in a humidified CO₂/air-incubator at 37°C in complete medium. After overnight incubation to allow cells adhesion, HMEC-1 were treated
for 24 h with/without 10% v/v OLNs, OFNs, and OSS, either in normoxic (20% O_2) or hypoxic (1% O_2) conditions. At the end of each treatment, cell supernatants were collected and used for the following analyses.

Evaluation of OLN uptake by HMEC-1

HMEC-1 were plated in 24-well plates on glass coverslips and incubated in complete medium for 24 h with/without 10% v/v FITC-labeled OLNs in a humidified CO_2/air-incubator at 37°C both in normoxic and hypoxic conditions. After 4′,6-diamidino-2-phenylindole (DAPI) staining to visualize cells nuclei, fluorescence images were acquired by a LSM710 inverted confocal laser scanning microscope equipped with a Plan-Neofluar 63×1.4 oil objective, that allowed a field view of at least 5 cells. Wavelength of 488 nm was used to detect OLNs, and of 460 nm to detect the labeled nuclei. The acquisition time was 400 ms.

Cytotoxicity studies

The potential cytotoxic effect of OLN and control formulations was measured as the release of lactate dehydrogenase (LDH) from HMEC-1 into the extracellular medium using the LDH Cytotoxicity Assay kit following the manufacturer’s instructions. LDH was measured both in the extracellular medium and in the cells pellet. Briefly, cells were incubated for 24 h with/without 10% v/v OLNs, OFNs or OSS, either in normoxic (20 % O_2) or hypoxic (1 % O_2) conditions, in a humidified CO_2/air-incubator at 37°C. Then, cell supernatants were collected and centrifuged at 13000g for 2 min. Cells were washed with PBS and resuspended in 0.5 ml of Triton X100 (2% final concentration) to lyse cells. One hundred microliters of this solution or 100 microliters of supernatant was mixed with 100 microliters of LDH reaction mix, containing the LDH substrate, and incubated for 10 min at room temperature in
the dark. Absorbance was then read at 450 nm with a reference wavelength of 650 nm using Synergy 4 microplate reader.

Cell viability studies

Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. HMEC-1 were incubated in complete medium overnight to allow the cells to adhere and then treated for 24 h with/without 10% v/v OLNs, OFNs or OSS, either in normoxic (20 % O\textsubscript{2}) or hypoxic (1 % O\textsubscript{2}) conditions, in a humidified CO\textsubscript{2}/air-incubator at 37°C in serum free medium. Thereafter, 20 µL of 5 mg/mL MTT in PBS were added to cells for 3 additional hours at 37 °C in the dark. The plates were then centrifuged, the supernatants discarded and the dark blue formazan crystals dissolved using 100 µL of lysis buffer containing 20 % (w/v) sodium dodecylsulfate, 40 % N,N-dimethylformamide (pH 4.7 in 80 % acetic acid). The plates were then read on Synergy 4 microplate reader at a test wavelength of 550 nm and at a reference wavelength of 650 nm.

Measurement of MMP-2, MMP-9, TIMP-1, and TIMP-2 production

HMEC-1 were incubated overnight in complete medium and then treated for 24 h with/without 10% v/v OLNs, OFNs or OSS, either in normoxic (20 % O\textsubscript{2}) or hypoxic (1 % O\textsubscript{2}) conditions, in a humidified CO\textsubscript{2}/air-incubator at 37°C in serum-free medium. Thereafter, cell supernatants were collected, and the levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 were assayed in 100 µl of HMEC-1 supernatants by specific ELISA. Standard calibration curves were generated with rhMMP-2, rhMMP-9, rhTIMP-1, and rhTIMP-2, according to the manufacturer’s instructions. Of note, ELISA kits could not distinguish between latent and active forms of MMP-2 and MMP-9. For this reason, a complementary analysis by gelatin zymography was performed, as described in the following paragraph.
Measurement of the levels of latent and active forms of gelatinases in cell supernatants

The levels of latent and active forms of gelatinases were evaluated by gelatin zymography in the cell supernatants as previously described [D’Alessandro et al., 2013]. Briefly, HMEC-1 were incubated overnight in complete medium and then treated for 24 h with/without 10% v/v OLNs, OFNs or OSS, either in normoxic (20 % O₂) or hypoxic (1 % O₂) conditions, in a humidified CO₂/air-incubator at 37°C in serum-free medium. Thereafter, 15 µl cell supernatants/lane were loaded on 8% polyacrylamide gels containing 0.1% gelatin under non-denaturing and non-reducing conditions. Following electrophoresis, gels were washed at room temperature for 2 h in milliQ water containing 2.5% (v/v) Triton-X100 and incubated for 18 h at 37°C in a collagenase buffer containing (mM): NaCl, 200; Tris, 50; CaCl₂, 10; and 0.018% (v/v) Brij 35, pH 7.5, with or without 5 mM ethylenediaminetetraacetic acid to exclude aspecific bands. At the end of the incubation, the gels were stained for 15 min with Coomassie blue (0.5% Coomassie blue in methanol/acetic acid/water at a ratio of 3:1:6). The gels were destained in milliQ water. Densitometric analysis of the bands, reflecting the total levels of latent and active forms of gelatinases, was performed using a computerized densitometer.

In vitro wound healing assay

In vitro wound healing assay was performed on HMEC-1 cells using Ibidi’s culture inserts according to the manufacturer’s instructions. One culture insert per well was placed in a 24-well plate. Then, 70 µl from a suspension of 5x10⁵ cells/ml HMEC-1 cells were plated in each chamber of Ibidi’s culture inserts with cell growth medium. After 24 h, culture inserts were detached resulting in two confluent monolayers, divided by a space (scratch) of 500 µm. Thereafter, cells were washed with PBS and incubated in fresh medium for 8 h in the
presence or absence of 10% v/v OLNs or OFNs, either in normoxic or hypoxic conditions. For each condition, at least two different culture inserts were employed. At the end of the observational period, scratch images were taken using a Nikon Ti-e eclipse microscope. Scratches were also measured and normalized with a time 0 scratch (500 µm).

Microvessel-like structures formation

HMEC-1 were evaluated for the ability to spontaneously migrate and self-organize in microvessel-like structures when cultured on a basal membrane surface [Prato et al., 2011]. Cells were seeded (1×10^5 cells/well) in a 96-well plate previously covered with solidified Cultrex (50µ/well), a growth factor-free basement membrane extract from murine Engelbreth-Holm-Swarm tumor. After 2 h of incubation in the presence or absence of 10% v/v OLNs, each well was evaluated by optical microscopy. The formation of microvessel-like structures was measured as the number of crosses between microvessel-like structures counted in five randomly selected fields by two independent observers.

Statistical analysis.

For each set of experiments, data are shown as means + SEM (LDH, MTT, densitometry, ELISA, and Cultrex assay results) or as a representative image (confocal microscopy and gelatin zymography results) of at least three independent experiments with similar results. All data were analyzed by a one-way analysis of variance (ANOVA) followed by Tukey's post-hoc test (software: SPSS 16.0 for Windows, SPSS Inc., Chicago, IL) or by Student’s t test.
Results

Characterization of dextran OLN preparations

Before use, all dextran-shelled OLN preparations were meticulously characterized for physico-chemical parameters. Results were always in line with published data [Prato et al., 2015]: OLNs displayed spherical shapes, 590 nm average diameters, −25 mV zeta potential, 1.33 as refractive index value, 1.59 e-3 Pa·s as viscosity value, and 5.43 e-2 mPa as shear modulus value, calculated at a shear rate value of 150 s⁻¹. OLNs also showed a good oxygen-storing capacity of 0.40 mg/ml of oxygen either before or after 20-min UV-C sterilization, and such an oxygen amount was comparable with that of OSS. Furthermore, all nanodroplet preparations proved to be stable over time, as confirmed by long-term checking of these parameters.

OLN uptake by human dermal microvascular endothelial cells

Confocal microscopy analysis was performed to determine whether OLNs were internalized by endothelial cells. HMEC-1 were incubated with 10% v/v FITC-labeled dextran-shelled OLNs or OFNs for 24 h in normoxic or hypoxic conditions. As shown in Figure 1, confocal microscopy confirmed OLN internalization by normoxic HMEC-1 and their localization in the cytoplasm. Similar results were also obtained upon culturing HMEC-1 cells with OLNs in hypoxic conditions and with OFNs both in normoxic or hypoxic conditions (data not shown).
FIGURE 1. OLN internalization by human dermal microvascular endothelial cells.

HMEC-1 (10^5 cells/0.5 ml MCDB 131 medium) were left untreated (upper panels) or treated with 10% v/v FITC-labeled OLNs (lower panels) for 24 h in normoxia (20% O_2). After DAPI staining, cells were checked by confocal microscopy. Results are shown as representative images from three independent experiments. Left panels: cell nuclei after DAPI staining. Central panels: FITC-labeled OLNs. Right panels: merged images. Magnification: 63X.

Effects of hypoxia and OLNs on HMEC-1 viability

After 24 h-incubation of HMEC-1 with or without 10% v/v OSS, OLNs or OFNs, both in normoxic (20% O_2) and hypoxic (1% O_2) conditions, cytotoxicity and cell viability were analyzed through LDH and MTT assays, respectively (Figure 2). As shown in Panel 2A, OSS, OLNs or OFNs were not toxic to HMEC-1 both in normoxic (20% O_2) and hypoxic
(1% O₂) conditions. As shown in Panel 2B, hypoxia per se determined an apparent reduction of the metabolic activity of HMEC-1, however such an effect was not statistically significant and in any case was fully counteracted by OLNs.

FIGURE 2. Hypoxia and OLN effects on human dermal microvascular endothelial cell viability. HMEC-1 (10⁵ cells/0.5 ml MCDB 131 medium) were left untreated or treated with 10% v/v OLNs, OFNs or OSS for 24 h in normoxia (20% O₂, black bars) or hypoxia (1% O₂, white bars). After collection of cell supernatants and lysates, the percentage of cytotoxicity was measured by the release of LDH (panel A), whereas the percentage of cell viability was measured with the MTT assay (panel B). The results are the means+SEM from three independent experiments. Using the ANOVA test, no significant differences between normoxic or hypoxic control cells or between OLN-treated and untreated cells were observed (both panels).
Hypoxia and OLN effects on gelatinase secretion by human dermal microvascular endothelial cells

After 24 h-incubation of HMEC-1 with or without 10% v/v OSS, OLNs or OFNs, both in normoxic (20% O$_2$) and hypoxic (1% O$_2$) conditions, the secretion of gelatinases (MMP-2 and MMP-9) into cell supernatants was evaluated by ELISA as well as by gelatin zymography coupled to densitometry. The results are shown in Figure 3. Untreated normoxic HMEC-1 constitutively secreted $\sim$400 pg/ml of MMP-2 (Panel A). Notably, HMEC-1 only secreted the 72 kDa latent form of MMP-2 (proMMP-2), whereas the 63 kDa active form was not detected in the cell supernatants (Panels B-C). On the contrary, neither ELISA (not shown) nor gelatin zymography analyses detected any MMP-9 protein amounts in endothelial cell supernatants. Hypoxia significantly altered MMP-2 secretion by almost doubling proMMP-2 levels in HMEC-1 supernatants. OLN – but not OFNs or OSS – fully reversed the effects of hypoxia, restoring a normoxia-like secretion of proMMP-2.
FIGURE 3. Effects of hypoxia and OLNs on MMP-2 secretion by human dermal microvascular endothelial cells. HMEC-1 (10^5 cells/0.5 ml MCDB 131 medium) were left

A: Graph showing changes in MMP-2 secretion with different treatments.

B: Western blot analysis of HMEC-1 supernatants under hypoxia and OLNs conditions.

C: Bar graph representing changes in pro-MMP-2 levels under normoxia and hypoxia conditions.
untreated or treated with 10% v/v OLNs, OFNs or OSS for 24 h in normoxia (20% O\textsubscript{2}; panels A and C: black bars; panel B: odd lanes) or hypoxia (1% O\textsubscript{2}; panels A and C: white bars; panel B: even lanes). After collection of cell supernatants, MMP-2 protein levels were quantified by ELISA (panel A), whereas MMP-2 latent/active forms were analyzed by gelatin zymography (panel B) and subsequent densitometry (panel C). For gelatin zymography, recombinant human proMMP-9 (92 kDa) was employed as a standard marker (st). Results are shown as means+SEM (panels A and C) or as a representative gel (panel B) from three independent experiments. ELISA and densitometric data were also evaluated for significance by ANOVA: * vs normoxic control cells: $p<0.0001$ (panel A), $p<0.0001$ (panel C); ° vs hypoxic control cells: $p<0.0001$ (panel A), $p<0.0001$ (panel C).

**Hypoxia and OLN effects on TIMP secretion by human dermal microvascular endothelial cells and MMP-2/TIMP-2 balances**

HMEC-1 were incubated for 24 h with or without 10% v/v OSS, OLNs or OFNs, both in normoxic (20% O\textsubscript{2}) and hypoxic (1% O\textsubscript{2}) conditions. Thereafter, the secretion of TIMP-1 and TIMP-2 was evaluated by ELISA. As shown in Figure 4, normoxic untreated HMEC-1 constitutively released $\sim 2.2$ ng/ml TIMP-1 and $\sim 1.6$ ng/ml TIMP-2. Hypoxia significantly lowered by almost 20% the secreted levels of TIMP-1 while TIMP-2 production was not affected. OLNs – but not OFNs and OSS - completely abrogated the effects of hypoxia, restoring physiological TIMP-1 amounts also in hypoxic culturing conditions.
FIGURE 4. Effects of hypoxia and OLNs on protein levels of gelatinase inhibitors (TIMP-1 and TIMP-2) secreted by human dermal microvascular endothelial cells. HMEC-1 (10^5 cells/0.5 ml MCDB 131 medium) were left untreated or treated with 10% v/v OLNs, OFNs or OSS for 24 h in normoxia (20% O_2; black bars, both panels) or hypoxia (1% O_2; white bars, both panels). After collection of cell supernatants, TIMP-1 (panel A) and TIMP-2 (panel B) protein levels were quantified by ELISA. Results are shown as means+SEM from three independent experiments. Data were also evaluated for significance by ANOVA: * vs normoxic control cells: p<0.0001 (panel A) and p not significant (panel B); ° vs hypoxic control cells: p<0.0001 (panel A) and p not significant (panel B).

Consequently, the balance between MMP-2 and its inhibitor was calculated. As shown in Figure 5, hypoxia significantly affected MMP-2/TIMP-2 stoichiometric ratio, which was almost doubled with respect to cells cultured in normoxic conditions. OLNs – but not OFNs
or OSS – effectively counteracted the effects of hypoxia, restoring the MMP-2/TIMP-2 ratio to a value similar to that observed in normoxia.

**FIGURE 5. Effects of hypoxia and OLNs on MMP-2/TIMP-2 balances upon secretion by dermal microvascular endothelial cells.** MMP-2/TIMP-2 stoichiometric ratio was calculated from the ELISA data (see Figures 3-4). Results are shown as means+SEM from three independent experiments. Data were also evaluated for significance by ANOVA: * vs normoxic control cells: \( p < 0.0001 \); ° vs hypoxic control cells: \( p < 0.0001 \).

**Effects of hypoxia and OLNs on migration and wound healing abilities of human dermal microvascular endothelial cells**

The ability of HMEC-1 to spontaneously migrate was investigated through an *in vitro* wound healing assay. As shown in Figure 6, hypoxic HMEC-1 displayed a lower ability to migrate
compared to normoxic cells. However, the migration ability of hypoxic HMEC-1 was significantly increased in the presence of OLNs. Interestingly, OLN effects were not reproduced by OFNs, suggesting a peculiar role for oxygen released from the core of OLNs.

**FIGURE 6.** Effects of hypoxia and OLNs on migration and wound healing abilities of human microvascular dermal endothelial cells. HMEC-1 were seeded in two confluent monolayers, divided by a space (scratch) of 500 µm, and incubated for 8 h in normoxia (20% O₂) or hypoxia (1% O₂) with/without 10% v/v OLNs or OFNs. Thereafter, scratch lengths were measured. A: representative images. B: means±SEM of scratch lengths. Results are from three independent experiments performed in duplicates. Data were also evaluated for significance by ANOVA: * vs normoxic untreated cells: *p* < 0.001; ° vs hypoxic untreated cells: *p* < 0.001.
Effects of hypoxia and OLNs on abilities of human dermal microvascular endothelial cells to invade collagen matrix and form microvessel-like structures

The ability of HMEC-1 to invade a collagen matrix and form microvessel-like structures was investigated through an in vitro invasion assay. As shown in Figure 7, hypoxic HMEC-1 displayed a lower ability to invade matrix and organize in microvessel-like structures compared to normoxic cells. However, the invasion ability (i.e. the number of crosses) of hypoxic HMEC-1 was significantly increased in the presence of OLNs.

**FIGURE 7.** Effects of hypoxia and OLNs on matrix invasion ability of human microvascular dermal endothelial cells. HMEC-1 (1x10^5 cells/0.5 ml MCDB 131 medium) were seeded on a Cultrex matrix and incubated for 2 h in normoxia (20% O_2) or hypoxia (1% O_2) with/without 10% v/v OLNs. Thereafter, microvessel-like structures were checked by optical microscopy and the number of crosses between two microvessel-like structures was counted in five fields. A: representative images. B: means+SEM of numbers of crosses.
Results are from four independent experiments. Data were also evaluated for significance by Student’s $t$ test: * vs hypoxic untreated cells: $p < 0.05$. 


Discussion

During healing processes, the balance between pro- and anti-angiogenic factors determining specific endothelial cell behavior and vessel organization must be spatially and temporally controlled. Among these factors, MMPs appear as pivotal molecules. These evolutionarily conserved and tightly regulated zinc-dependent proteases are expressed either in a constitutive or inducible manner by a broad spectrum of specialized cells, including endothelial cells [Vandenbroucke et al., 2014]. Released as latent zymogens, activated locally by other proteases and inhibited in a 1:1 stoichiometric ratio by their secreted endogenous inhibitors (TIMPs) [Brew & Nagase, 2010], MMPs not only process all the components of the basement membrane and the ECM, but can also cleave cytokines, chemokines, growth factors, enzymes, and membrane-bound proteins, thus promoting their activation, inhibition, degradation or shedding [Cauwe et al., 2007]. As such, they play essential roles in cell survival, proliferation, migration, invasion, hemostasis and inflammation within the cellular milieu of the wound [Gill & Parks, 2008].

A long-lasting hypoxic environment represents a critical feature of chronic wounds [4-5]. However, the effects of hypoxia on the phenotype and the behavior of the cellular environment of the wound can be dramatically different depending on the considered cell type (monocytes, keratinocytes, endothelial cells, fibroblasts etc). To complement previous data on hypoxia-dependent dysregulation of MMP/TIMP balances in human monocytes [Gulino et al., 2015] and keratinocytes [Khadjavi et al., 2015], the present in vitro study aimed at investigating the effects of hypoxia on the pro-angiogenic phenotype and the wound healing abilities of human dermal microvascular endothelial cells. Furthermore, innovative and nonconventional dextran-shelled/DFP-cored OLNs were challenged for their potential abilities to counteract the effects of hypoxia.
Normoxic HMEC-1 constitutively secreted MMP-2, TIMP-1, and TIMP-2 proteins while MMP-9 was not observed. In particular, cells were found to constitutively release only the latent 72 kDa form of MMP-2, whereas its 62 kDa activated form was not detected. These results are in line with previous reports on endothelial cells from both micro- and macro-vascular vessels [Hanemaaijer et al., 1993; Ben-Yosef et al., 2002; Ben-Yosef et al., 2005; Bertl et al., 2006]. Exposure of endothelial cells to prolonged hypoxia led to enhanced MMP-2 and diminished TIMP-2 protein levels in cell supernatants, whereas TIMP-1 production was not altered. The increase of MMP-2 resulted in elevated zymogen secretion but not in the active form of the enzyme. Notably, latent MMP-2 undergoes activation mainly through interactions with membrane-bound MT1-MMP and the $\alpha_v\beta_3$ integrin [Deryugina et al., 2001; Hofmann et al., 2008]. Additionally, low levels of TIMP-2, the main MMP-2 inhibitor, participate in MT1-MMP-mediated activation of MMP-2, while high levels of TIMP-2 can block MMP-2 activation [Brew & Nagase, 2010]. Interestingly, hypoxia-dependent down-regulation of MT1-MMP expression was previously reported for human endothelial cells [Ben-Yosef et al., 2002]. This might justify the absence of the active 62 kDa form of MMP-2 in the present hypoxic model.

HMEC-1 were also challenged under hypoxic conditions for their ability to migrate, invade the ECM and form tube-like structures. Indeed, ECM structure and composition provides a scaffold and signals for cell adhesion and migration during tissue restoration [Li et al., 2005]. ECM effect on angiogenesis appears highly variable over time, strictly depending on protein constituents, protease actions, and ECM ability to sequester growth factors and bioactive molecular fragments [Wells et al., 2015]. Significantly, MMP-mediated degradation of ECM can promote endothelial cell migration through exposure of pro-migratory matrix molecule binding sites [Pepper, 2001; Hangai et al., 2002]. However, in the present work hypoxic HMEC-1 displayed lower abilities to migrate and promote wound healing, as well as to...
invade a collagen matrix and organize in tube-like structures compared to normoxic cells, despite increased MMP-2 levels. Interestingly, similar results were obtained by Ben-Yosef and colleagues in a previous work using endothelial cells from large caliber vessels, where hypoxia led concurrently to an increase in proMMP-2 secretion and to a significant reduction in the number of tube-like structures spontaneously formed in the culture [Ben-Yosef et al., 2005]. Since specific MMP-2 inhibitors did not restore the normal tube-like formation, the authors concluded that hypoxia-induced anti-angiogenic effects responsible for the observed reduction in tube-like formation were not mediated by MMP-2. Consistently, in another in vitro model, tube-like formation in human microvascular endothelial cells was shown to depend directly on membrane-bound MT1-MMP and not on secreted MMPs such as MMP-2 [Koike et al, 2002]. Therefore, the compromised migration and invasion abilities of HMEC-1 highlighted here might be secondary to hypoxia-induced reduction of MT1-MMP, previously reported for endothelial cells [Ben-Yosef et al., 2002]. On the other hand, in chronic wounds, reduced protein levels compared to acute wounds have been described for several growth factors including FGF, EGF, PDGF, VEGF, and TGF-β, secondary to trapping by ECM molecules or excessive degradation by MMPs [Greaves et al., 2013]. Importantly, many of these growth factors are MMP-2 substrates, including TGF-β, released after decorin cleavage [Cauwe et al., 2009; Imai et al., 1997]. Once ascertained that hypoxia hampers HMEC-1 pro-angiogenic phenotype and behavior by increasing MMP-2/TIMP-2 stoichiometric ratio and reducing cell migration and ECM invasion abilities, new dextran-shelled OLNs [Prato et al., 2015] were challenged for their therapeutic potential to counteract the effects of hypoxia. The core structure of these innovative and nonconventional gas nanocarriers is constituted by DFP, a stable and biologically inert liquid fluorocarbon which carries molecular oxygen without actually binding it, thus favoring gas exchange [Cote et al., 2008]. On the other hand, OLN shell is
constituted by dextran, a well-known polysaccharide classified as class 4 (low-toxicity) substance [Bos et al., 2005]. OLNs are able to release significant amounts of oxygen into hypoxic environments in a time-sustained manner, opposite to OSS, which releases oxygen only transiently, and to OFNs, not releasing oxygen at all [Prato et al., 2015]. All sterile nanodroplet preparations employed here displayed spherical shapes, nanometric sizes, negative charges, high stability over time, and good oxygen-storing and -releasing abilities, in accordance with literature data [Prato et al., 2015].

OLNs were internalized by HMEC-1 into the cytoplasmic region, not entering the nuclei. This evidence complements previous data on the uptake of OLNs by other eukaryotic cells, including human keratinocytes [Prato et al., 2015, Khadjavi et al., 2015] and monocytes [Gulino et al., 2015]. OLNs did not display cytotoxic effects on HMEC-1. Even more so, OLNs fully abrogated hypoxia-dependent dysregulating effects on proteolytic activity, restoring normoxia-like balances between MMP-2 and TIMP-1/2 and improving migration and ECM invasion abilities. These effects were specifically dependent on time-sustained oxygen release from the inner core of OLNs, since they were not reproduced after treatment with OFNs or OSS. These results are in full agreement with those obtained from parallel works with dextran-shelled OLNs, able to restore normoxia-like MMP-9/TIMP-1 ratio in hypoxic human monocytes [Gulino et al., 2015], and chitosan-shelled OLNs, effective in abrogating hypoxia-dependent dysregulation of balances between gelatinases and their inhibitors in human keratinocytes [Khadjavi et al., 2015]. Therefore, the findings proposed here appear extremely relevant to reach a global vision of the pro-angiogenic phenotype of the chronic wound, since endothelial cells play relevant roles during healing processes in concert with both monocytes and keratinocytes [Eming et al., 2014].

In conclusion, the present work shows that prolonged hypoxia significantly alters the phenotype and behavior of human dermal microvascular endothelium, enhancing MMP-2 and
reducing TIMP-1 secretion, and compromising cell abilities to migrate, promote wound healing, invade the ECM and form tube-like structures. These findings enlarge the available knowledge on the effects of hypoxia on the pro-angiogenic profile of single cell populations actively involved in wound healing processes, thus helping to better understand the dynamics occurring at the milieu of the hypoxic chronic wound. Intriguingly, dextran-shelled/DFP-cored OLNs proved effective in counteracting hypoxia, reestablishing normoxia-like pro-angiogenic features in hypoxic microvascular endothelial cells. As such, these results support the proposal that OLNs should be tested as innovative, nonconventional, cost-effective, and nontoxic adjuvant therapeutic tools for chronic wound treatment, in order to promote or accelerate tissue repair and the regeneration processes. Based on the present in vitro evidence, future preclinical studies to translate OLN technology to clinical practice are envisaged.
Acknowledgements

We gratefully acknowledge the Compagnia di San Paolo (Ateneo-San Paolo 2011 ORTO11CE8R grant to CG and MP) and Università degli Studi di Torino (ex-60% 2013 intramural funds to GG and MP) for funding support to this work. MP holds a professorship granted by Università degli Studi di Torino and Azienda Sanitaria Locale-19 (ASL-19). AK and MP are funded by a partnership grant from the European Community and the Italian Ministry of Instruction, University, and Research (CHIC grant no. 600841). NB and SDA research is supported by the Italian Ministry of Instruction, University, and Research (PRIN 2013 grant). The authors are sincerely grateful to Adriano Troia for his suggestions on nanodroplet manufacturing, to Donatella Taramelli for her comments on the manuscript, and to Ghislain Opdenakker and Philippe Van den Steen for kindly giving recombinant human proMMP-9. The authors have no conflicting financial interests.
List of Abbreviations

ANOVA, analysis of variance; DAPI, 4',6-diamidino-2-phenylindole; DFP, 2H,3H-decafluoropentane; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ECM, extracellular matrix; FITC, fluorescein isothiocyanate; LDH, lactate dehydrogenase; MMP, matrix metalloproteinase; OFN, oxygen-free nanodroplet; OLN, oxygen-loaded nanodroplet; OSS, oxygen-saturated solution; PBS, phosphate-buffered saline; PFP, perfluoropentane; TIMP, tissue inhibitor of metalloproteinase; US, ultrasound; UV, ultraviolet.
References


